Search alternatives:
progress decrease » progressive decrease (Expand Search), problems decreased (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
progress decrease » progressive decrease (Expand Search), problems decreased (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
-
41
MiR-129-5p levels were decreased in mouse depression models.
Published 2025“…</b> The KEGG pathway analysis identifies the number of target genes within each pathway. Those with a p-value < 0.05 are considered significant. <b>L.…”
-
42
-
43
-
44
-
45
Cinacalcet administered early in the inactive phase markedly decrease parathyroid Ki-67 index.
Published 2025“…All groups were compared by Kruskal Wallis test with <i>post hoc</i> test after Dunn with Bonferroni adjustment showing significant decreased Ki-67 labeling index of <i>Cina1</i> compared to <i>Cina2</i> (p = 0.006) and the untreated CKD groups (p = 0.0001 and p = 0.0002, respectively). …”
-
46
The body weight and cholesterol levels of the mice were recorded before the administration of the drug.
Published 2025Subjects: “…attenuates fibrosis progression…”
-
47
Effects of Kylo-0603 on body weight, organ weight, and body fat content.
Published 2025Subjects: “…attenuates fibrosis progression…”
-
48
Table 2_Expression and prognostic significance of the m6A RNA methylation regulator HNRNPC in HNSCC.docx
Published 2025“…Knockdown of HNRNPC in the HNSCC cell lines HSC-3 and CAL-27 resulted in a significant decrease in proliferation, invasion, and malignant transformation abilities. …”
-
49
Table 1_Expression and prognostic significance of the m6A RNA methylation regulator HNRNPC in HNSCC.docx
Published 2025“…Knockdown of HNRNPC in the HNSCC cell lines HSC-3 and CAL-27 resulted in a significant decrease in proliferation, invasion, and malignant transformation abilities. …”
-
50
After 8 weeks of treatment, body fat analysis and bone mineral density testing of mice in each group.
Published 2025Subjects: “…attenuates fibrosis progression…”
-
51
Pharmacological efficacy of Kylo-0603 in MASH mouse models (F2 ~ 3).
Published 2025Subjects: “…attenuates fibrosis progression…”
-
52
-
53
The Chol and TG content in liver homogenates of the mice in each group after 2 and 10 weeks of drug intervention.
Published 2025Subjects: “…attenuates fibrosis progression…”
-
54
Hematoxylin and eosin (H&E) staining, Sirius Red staining, and Oil Red staining of liver tissues from mice in each group after 8 weeks of treatment with either vehicle or Kylo-0603...
Published 2025Subjects: “…attenuates fibrosis progression…”
-
55
-
56
-
57
-
58
-
59
-
60